GUIDE-IT NT-proBNP-Guided Therapy Algorithm

Clinical calculation support · Verify results before clinical use

Patient data and biomarker target

Compare NT-proBNP with a selected target. This tool does not calculate a validated risk score or prescribe treatment.

<1,000pg/mL trial target
Context only; LVEF is not used to calculate a GUIDE-IT score.
Default: 1,000 pg/mL, the GUIDE-IT target. Target achievement uses a strict < comparison.
Documentation only; medications are not automatically evaluated.

Clinical context and use

GUIDE-IT (Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure) tested whether adjusting evidence-based heart-failure therapy to achieve NT-proBNP below 1,000 pg/mL improved outcomes in high-risk patients with heart failure with reduced ejection fraction (HFrEF).

The randomized trial did not demonstrate a significant improvement in its primary endpoint of time to cardiovascular death or first heart-failure hospitalization with biomarker-guided treatment compared with high-quality usual care. NT-proBNP can support assessment and follow-up, but a target-based strategy should not replace clinical evaluation or guideline-directed treatment.

Practical interpretation

  • Assess symptoms, examination findings, and congestion before interpreting a result.
  • Review renal function, rhythm (including atrial fibrillation), age, body composition, and other factors affecting NT-proBNP.
  • Optimize guideline-directed medical therapy according to current guidelines, contraindications, blood pressure, renal function, potassium, and tolerance—not from the biomarker result alone.
  • Compare serial measurements in clinical context and, when practical, using the same assay.
  • Do not apply the GUIDE-IT target indiscriminately to HFpEF, acute diagnostic settings, or populations unlike the trial cohort.

Scope and limitations

This tool validates entered values and compares NT-proBNP with a user-selected target. It does not reproduce the full GUIDE-IT protocol, calculate outcome probabilities, determine medication doses, or provide a validated treatment recommendation.

Evidence and references

Felker GM, Anstrom KJ, Adams KF, et al. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.JAMA. 2017;318(8):713–720. Primary GUIDE-IT trial report. DOI: 10.1001/jama.2017.10565; PMID: 28829876.
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063.
Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial.JAMA Cardiology. 2020. Secondary analysis of treatment optimization in GUIDE-IT. PubMed: 32319999.
Clinical disclaimer: For educational and decision-support use only. This output is not a validated risk score and does not replace clinician assessment, local protocols, or current guidelines. Consult the original publication and applicable guidance before clinical use.